{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:18Z","timestamp":1791438078199,"version":"4.3.3"},"reference-count":36,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with advanced MCC (aMCC) in clinical trials. To date, only results from clinical trials, patients treated in an expanded access program and very small numbers of patients have been reported. In this study, detailed real-world efficacy and toxicity data of avelumab in patients with aMCC are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with aMCC treated in four dedicated referral centers in the Netherlands were analyzed from February 2017 until December 2019. Patients were included if they had received at least one administration of avelumab, regardless of previous lines of therapy. Patient data were collected retrospectively from patient records. Primary endpoints were response rate (RR) and duration of response (DOR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-four patients received avelumab. Eight (15%) patients had locally advanced disease (laMCC). In 40 (74%) patients, avelumab was first-line treatment, these included all patients with laMCC. The median follow-up was 8.9 (range 0.5\u201335.9) months. RR was 57% (n=31) with 24% (n=13) of patients achieving a complete response. The median DOR was 8.4 (range 1.3\u201322.1) months and 23 (43%) patients had an ongoing response at the end of the study. The median PFS was 8.6 (95% CI 1.6\u201315.5) months, and the median OS was 25.8 (95% CI 9.1\u201342.4) months. Six (11%) patients experienced grade 3 toxicity. No grade 4\u20135 toxicity was seen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this real-world cohort, clinical efficacy and toxicity outcomes in clinical practice were in line with results from clinical trials and showed relatively high RRs and durable responses in patients with aMCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001076","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T17:45:28Z","timestamp":1600451128000},"page":"e001076","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-2074","authenticated-orcid":false,"given":"Sonja","family":"Levy","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J B","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Maastricht University Medical Center+, Maastricht, Limburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A L M","family":"Eskens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien B M I","family":"Keymeulen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Center+, Maastricht, Limburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas B","family":"Been","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot E T","family":"Tesselaar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"2025100307582468000_8.2.e001076.1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100307582468000_8.2.e001076.2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/bjd.14950","article-title":"Epidemiological trends in Merkel cell carcinoma in southern France: a registry-based study","volume":"176","author":"Fondain","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025100307582468000_8.2.e001076.3","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1111\/ajd.13131","article-title":"Trends in the incidence of Merkel cell carcinoma in Victoria, Australia, between 1986 and 2016","volume":"61","author":"Garbutcheon-Singh","year":"2020","journal-title":"Australas J Dermatol"},{"key":"2025100307582468000_8.2.e001076.4","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jdv.14798","article-title":"Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey","volume":"32","author":"Fondain","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025100307582468000_8.2.e001076.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.056"},{"key":"2025100307582468000_8.2.e001076.6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1245\/s10434-012-2779-3","article-title":"Merkel cell carcinoma: 30-year experience from a single institution","volume":"20","author":"Santamaria-Barria","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2025100307582468000_8.2.e001076.7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"key":"2025100307582468000_8.2.e001076.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"2025100307582468000_8.2.e001076.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1152586"},{"key":"2025100307582468000_8.2.e001076.10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181aa30a5"},{"key":"2025100307582468000_8.2.e001076.11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1338237","article-title":"Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma","volume":"6","author":"Schadendorf","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100307582468000_8.2.e001076.12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1877"},{"key":"2025100307582468000_8.2.e001076.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4159"},{"key":"2025100307582468000_8.2.e001076.14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6494"},{"key":"2025100307582468000_8.2.e001076.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0450-7"},{"key":"2025100307582468000_8.2.e001076.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line Avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a Preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100307582468000_8.2.e001076.17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100307582468000_8.2.e001076.18","unstructured":"EMA . Summary Of Opinion - Initial Authorisation of Avelumab. Committee for Medicinal Products for Human Use 2017(EMA\/CHMP\/426201\/2017)."},{"key":"2025100307582468000_8.2.e001076.19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000313"},{"key":"2025100307582468000_8.2.e001076.20","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.60"},{"key":"2025100307582468000_8.2.e001076.21","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181d97836"},{"key":"2025100307582468000_8.2.e001076.22","unstructured":"LMv V , Bertolli E , Korse C , et al . The clinical utility of neuron-specific enolase serum levels as a biomarker for Merkel cell carcinoma. Presented at ASCO 2019."},{"key":"2025100307582468000_8.2.e001076.23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00262-018-02295-4","article-title":"Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma","volume":"68","author":"D'Angelo","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100307582468000_8.2.e001076.24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000674"},{"key":"2025100307582468000_8.2.e001076.25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0134"},{"key":"2025100307582468000_8.2.e001076.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02108-X"},{"key":"2025100307582468000_8.2.e001076.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.329"},{"key":"2025100307582468000_8.2.e001076.28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5266-4"},{"key":"2025100307582468000_8.2.e001076.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129476"},{"key":"2025100307582468000_8.2.e001076.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.036"},{"key":"2025100307582468000_8.2.e001076.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.04.061"},{"key":"2025100307582468000_8.2.e001076.32","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0310-x"},{"key":"2025100307582468000_8.2.e001076.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1678"},{"key":"2025100307582468000_8.2.e001076.34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaad.2012.07.035","article-title":"Unknown primary Merkel cell carcinoma: 23 new cases and a review","volume":"68","author":"Tarantola","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025100307582468000_8.2.e001076.35","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/jso.25090","article-title":"Merkel cell carcinoma: clinical outcome and prognostic factors in 351 patients","volume":"117","author":"van Veenendaal","year":"2018","journal-title":"J Surg Oncol"},{"key":"2025100307582468000_8.2.e001076.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.iotech.2019.11.002","article-title":"Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response","volume":"4","author":"Hooiveld-Noeken","year":"2019","journal-title":"Immuno-Oncology Technology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:58:37Z","timestamp":1759503517000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,18]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/jitc-2020-001076"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001076","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}